
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Huntington’s Disease Treatment Market**

According to Intelli, the U.S. Huntington’s Disease Treatment Market size was valued at USD 285.99 Million in 2024 and is projected to reach USD 1,577.05 Million by 2032, growing at a CAGR of 21.49% from 2025 to 2032.



Huntington’s Disease (HD) is a progressive, devastating inherited neurological disorder that causes the gradual breakdown of nerve cells in the brain. In the U.S, approximately 30,000 individuals are currently living with Huntington’s Disease, while an estimated 200,000 more are at risk of inheriting the condition. These figures highlight the significant impact of HD within the U.S., emphasizing the need for continued research and support for affected individuals and their families. This degeneration leads to a wide range of physical, cognitive, and psychiatric symptoms. Symptoms typically begin to appear between the ages of 30 and 50. It is caused by a genetic mutation in the HTT gene. The mutation involves an expansion of the CAG trinucleotide repeat in the gene. HD is passed from parent to child in an autosomal dominant pattern that means a child has a 50% chance of inheriting the faulty gene if one parent carries it. This single genetic mutation triggers a gradual and unstoppable decline in brain function, with symptoms often appearing in mid-adulthood, though they can begin at any stage of life. As HD advances, individuals often face uncontrollable movements, problems with coordination and balance, cognitive decline affecting memory and decision-making, and emotional challenges like depression, anxiety, or irritability. HD is more than a medical diagnosis, stands as a profound testament to the influence of genetics and the unwavering strength of those who live with its challenges.

**U.S. Huntington’s Disease Treatment Market Definition**

The U.S. Huntington's Disease Treatment Market encompasses the healthcare sector dedicated to the research, development, approval, and commercialization of therapeutic interventions aimed at managing and treating HD. The rapid growth of the branded segment in the HD treatment market is largely driven by its proven clinical effectiveness and widespread brand trust among healthcare providers and patients. Leading market players are driving growth by implementing strategic initiatives such as launching innovative products and forming strategic partnerships to strengthen their market presence and increase share.

A close-up of hands holding a tablet and a pen

Description automatically generated

**U.S. Huntington’s Disease Treatment Market Overview**

The U.S. Huntington’s Disease (HD) treatment market is experiencing significant growth, driven by rising disease prevalence, advancements in genetic research, and increasing awareness of available treatment options. The U.S accounts for over 70% of the HD treatment market, exceeding the combined market share of major global regions including Germany, Spain, Italy, France, the United Kingdom, and Japan. The key components of this market include pharmacological intervention, Off-label drug, and healthcare services.

Ongoing clinical trials and a robust pipeline of drug candidates are key market trends contributing to future expansion. In addition, the approval of new treatments by the U.S. Food and Drug Administration (FDA) enhances therapeutic options and market dynamics.

Strategic collaborations, partnerships, are also playing a significant role in shaping the market, while improved healthcare infrastructure and patient support programs contribute to broader access and enhanced quality of care.

**U.S. Huntington’s Disease Treatment Market Segmentation**

U.S. Huntington’s Disease Treatment Market is segmented based on drug therapy, treatment, age and end-user.

**U.S. Huntington’s Disease Treatment Market, By Drug type**

* **Approved Drugs**
* **Tetrabenazine**
* **Deutetrabenazine**
* **Antipsychotics (Risperidone, Quetiapine)**
* **Antidepressants**
* **Pipeline Drugs**
* **Gene therapies**
* **RNA-based therapies**

The U.S. Huntington’s Disease treatment market is categorized by drug type into approved drugs and pipeline therapies, each playing a vital role in addressing the complex symptoms of the disorder. Among the approved treatments, Tetrabenazine and Deutetrabenazine are widely used to manage chorea, a hallmark motor symptom of Huntington’s Disease. It A close-up of hands holding a tablet and a pen

Description automatically generatedholds the maximum revenue in the segment. Meanwhile, the pipeline is rapidly evolving with promising innovations such as gene therapies and RNA-based treatments, aiming not only to manage symptoms. This dynamic and emerging therapies is driving significant momentum in the U.S. Huntington’s Disease treatment market.

**U.S. Huntington’s Disease Treatment Market, By Treatment Type**

* **Symptomatic Treatment**
* **Disease-Modifying Treatment**

The U.S. Huntington’s Disease treatment market is segmented into symptomatic treatments and disease-modifying treatments. Symptomatic treatments remain the cornerstone of care, focusing on managing the motor, cognitive, and psychiatric symptoms associated with the disease. This growth is driven by the widespread availability of symptom management therapies and the continued patent protection. It supports their market exclusivity. On the other side, the disease-modifying therapies segment is expected to experience the most rapid growth throughout the forecast period. Unlike symptomatic therapies that provide temporary relief, these treatments target the underlying genetic and molecular mechanisms responsible for disease progression. Current research in this area includes gene therapies, RNA interference, and antisense oligonucleotides, all designed to reduce the production of the mutant huntingtin (mHTT) protein, the root cause of the disease.

**U.S. Huntington’s Disease Treatment Market, By Age**

* **Below 60 years**
* **Above 60 years**

The U.S. Huntington’s Disease treatment market can be segmented by age into two primary groups, individuals below 60 years and those above 60 years. The below 60 age group accounts for a significant share of the market, as Huntington’s Disease symptoms typically emerge between the ages of 30 and 50. Meanwhile, the above 60 age group represents a growing segment due to increased life expectancy and improved diagnostic awareness, which leads to later-life identification and treatment.

**U.S. Huntington’s Disease Treatment Market, By End User**

* A close-up of hands holding a tablet and a pen

  Description automatically generated**Hospitals**
* **Specialty Clinics**
* **Homecare Settings**
* **Research & Academic Institutes**

The U.S. Huntington’s Disease treatment market is segmented by end users into hospitals, specialty clinics, homecare settings, and research & academic institutes. Hospitals dominate the market due to their comprehensive care facilities, access to specialized neurology departments. Specialty clinics, particularly those focused on neurology and movement disorders, are rapidly gaining traction by offering personalized, outpatient-based care and advanced treatment options. Meanwhile, research and academic institutes play a pivotal role in driving innovation, contributing to clinical trials, and accelerating the development of disease-modifying therapies.

**Key Players**

The “U.S. Huntington’s Disease Treatment Market” study report will provide valuable insight emphasizing the U.S market. The major players in the market are Teva Pharmaceutical Industries Ltd., Novartis AG, Neurocrine Biosciences, Inc., Eisai Co.Ltd., Sun Pharmaceutical Industries Ltd., H. Lundbeck A/S, Bausch Health Companies Inc., Dr. Reddy’s Laboratories Ltd., Lupin, Hetero, Roche Ltd., Prilenia Therapeutic, Neurocrine Biosciences, Annexon, Inc., Atalanta Therapeutics, Neurimmune AG among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In December 2024, Novartis signed a landmark licensing deal with PTC Therapeutics, valued at up to $2.9 billion for PTC518, an investigational oral therapy designed to target the mutant huntingtin protein in Huntington’s disease.
* In February 2025, MMJ International Holdings reached a major milestone with MMJ-002, its cannabis-derived softgel capsule containing THC, CBD, and other phytocannabinoids. This innovation is moving closer to commercialization as a potential treatment for Huntington’s disease.

A close-up of hands holding a tablet and a pen

Description automatically generated**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Huntington’s Disease Treatment Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the U.S. Huntington’s Disease Treatment Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generated**TABLE OF CONTENT**

**1 INTRODUCTION OF U.S. HUNTINGTON’S DISEASE TREATMENT MARKET**

1.1 Overview of the Market

1.2 Scope of Report

1.3 Assumptions

**2 EXECUTIVE SUMMARY**

**3 RESEARCH METHODOLOGY**

3.1 Data Mining

* 1. Validation

3.3 Primary Interviews

3.4 List of Data Sources

**4** **U.S. HUNTINGTON’S DISEASE TREATMENT MARKET OUTLOOK**

4.1 Overview

4.2 Market Dynamics

### 4.2.1 Drivers

### 4.2.2 Restraints

### 4.2.3 Opportunities

### 4.2.4 Trends

**A close-up of hands holding a tablet and a pen

Description automatically generated**4.3 Porters Five Force Model

* 1. **A close-up of hands holding a tablet and a pen

     Description automatically generated**Value Chain Analysis

1. **U.S. HUNTINGTON’S DISEASE TREATMENT MARKET, BY DRUG TYPE**

5.1 Overview

5.2 Approved Drugs

5.2.1 Tetrabenazine

5.2.2 Deutetrabenazine

5.2.3 Antipsychotics (Risperidone, Quetiapine)

5.2.4Antidepressants

5.3 Pipeline Drugs

5.3.1 Gene therapies

5.3.2 RNA-based therapies

**6 U.S. HUNTINGTON’S DISEASE TREATMENT MARKET, BY TREATMENT TYPE**

6.1Overview

6.2 Symptomatic Treatment

* 1. Disease-Modifying Treatment

**7 U.S. Huntington’s Disease Treatment Market, By Age**

7.1 Overview

7.2Below 60 years

7.3 Above 60 years

**A close-up of hands holding a tablet and a pen

Description automatically generated8 U.S. HUNTINGTON’S DISEASE TREATMENT MARKET, BY END USER**

8.1 Overview

8.2 Hospitals

8.3 Specialty Clinics

8.4 Homecare Settings

8.5 Research & Academic Institutes

**9 U.S. HUNTINGTON’S DISEASE TREATMENT MARKET COMPETITIVE LANDSCAPE**

9.1 Overview

* 1. Company Market Ranking
  2. Key Development Strategies

1. **COMPANY PROFILES**

**10.1 Teva Pharmaceutical Industries Ltd**

10.1.1Overview

### 10.1.2 Financial Performance

### 10.1.3 Product Outlook

### 10.1.4 Key Developments

**10.2 Novartis AG**

### 10.2.1 Overview

### 10.2.2 Financial Performance

### 10.2.3 Product Outlook

### 10.2.4 Key Developments

**10.3 Neurocrine Biosciences, Inc**

### A close-up of hands holding a tablet and a pen Description automatically generated10.3.1 Overview

### 10.3.2 Financial Performance

### 10.3.3 Product Outlook

### 10.3.4 Key Developments

**10.4 Eisai Co.Ltd**

### 10.4.1 Overview

### 10.4.2 Financial Performance

### 10.4.3 Product Outlook

### 10.4.4 Key Developments

**10.5 Sun Pharmaceutical**

### 10.5.1Overview

### 10.5.2 Financial Performance

### 10.5.3 Product Outlook

### 10.5.4 Key Developments

**10.6 H. Lundbeck A/S**

### 10.6.1 Overview

### 10.6.2 Financial Performance

### 10.6.3 Product Outlook

### 10.6.4 Key Development

**10.7 Bausch Health Companies Inc**

### A close-up of hands holding a tablet and a pen Description automatically generated10.7.1 Overview

### 10.7.2 Financial Performance

### 10.7.3 Product Outlook

### 10.7.4 Key Developments

**10.8 Dr. Reddy’s Laboratories Ltd**

### 10.8.1 Overview

### 10.8.2 Financial Performance

### 10.8.3 Product Outlook

### 10.8.4 Key Developments

**10.9 Lupin**

### 10.9.1 Overview

### 10.9.2 Financial Performance

### 10.9.3 Product Outlook

### 10.9.4 Key Development

**10.10 Hetero**

### Overview

### 10.10.2 Financial Performance

### 10.10.3 Product Outlook

### Key Development

**10.11 Roche Ltd.**

### 10.11.01Overview

### 10.11.2 Financial Performance

### 10.11.3 Product Outlook

### Key Development

A close-up of hands holding a tablet and a pen

Description automatically generated**10.12 Prilenia Therapeutic**

### 10.12.1Overview

### 10.12.2 Financial Performance

### 10.12.3 Product Outlook

### 10.12.4 Key Development

**10.13 Neurocrine Biosciences**

### 10.13.1 Overview

### 10.13.2 Financial Performance

### 10.13.3 Product Outlook

### 10.13.4 Key Development

**10.14 Annexon, Inc.**

### 10.14.1Overview

### 10.14.2 Financial Performance

### 10.14.3 Product Outlook

### 10.14.4 Key Development

**10.15 Atalanta Therapeutics**

### 10.15.1Overview

### 10.15.2 Financial Performance

### 10.15.3 Product Outlook

### 10.15.4 Key Development

**10.16 Neurimmune AG**

### 10.16.1Overview

### 10.16.2 Financial Performance

### 10.16.3 Product Outlook

### 10.16.4 Key Development

1. **KEY DEVELOPMENTS**

11.1Product Launches/Developments

11.2Mergers and Acquisitions

11.3 Business Expansions

**A close-up of hands holding a tablet and a pen

Description automatically generated** 11.4 Partnerships and Collaborations

**12 Appendix**

12.1Related Research